Related Experiment Video
Updated: Aug 9, 2026
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
Published on: November 8, 2016
Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy
Raquel Paris1, Albert Morales, Olga Coll
1Liver Unit, Instituto de Malalties Digestives, Servicio de Radioterapia, Hospital Clinic i Provincial, Instituto Investigaciones Biomedicas August Pi, Consejo Superior de Investigaciones Cientificas, Barcelona 08036, Spain.
Abstract:
Ganglioside GD3 (GD3) has emerged as a modulator of cell death pathways due to its ability to interact with mitochondria and disable survival pathways. Because NF-kappaB activation contributes to cancer therapy resistance, this study was undertaken to test whether GD3 modulates the response of human hepatoblastoma HepG2 cells to radio- and chemotherapy. NF-kappaB was activated in HepG2 cells shortly after therapeutic doses of ionizing radiation or daunorubicin treatment that translated into up-regulation of kappaB-dependent genes. These effects were accompanied by minimal killing of HepG2 cells by either ionizing radiation or daunorubicin. However, GD3 pretreatment blocked the nuclear translocation of active kappaB members, without effect on Akt phosphorylation, induced by either treatment. The suppression of kappaB-dependent gene induction by GD3 was accompanied by enhanced apoptotic cell death caused by these therapies. Furthermore, the combination of GD3 plus ionizing radiation stimulated the formation of reactive species followed by the mitochondrial release of cytochrome c and Smac/Diablo and caspase 3 activation. Pretreatment with cyclosporin A before radiotherapy protected HepG2 cells from the therapeutic combination of GD3 plus ionizing radiation. These findings underscore a key role of mitochondria in the response of tumor cells to cancer therapy and highlight the potential relevance of GD3 to overcome resistance to cancer therapy by combining its dual action as a mitochondria-interacting and NF-kappaB-inactivating agent.
Insights
Ganglioside GD3 enhances cancer therapy effectiveness by blocking NF-kappaB activation and promoting apoptosis. This study shows GD3 sensitizes hepatoblastoma cells to radiation and chemotherapy, overcoming treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Ganglioside GD3 (GD3) influences cell death pathways by interacting with mitochondria and inhibiting survival signals.
- Nuclear factor kappa B (NF-kappaB) activation is linked to resistance to cancer therapies.
- Understanding GD3's role in modulating therapy response is crucial for developing new cancer treatments.
Purpose of the Study:
- To investigate whether GD3 affects the response of human hepatoblastoma HepG2 cells to radio- and chemotherapy.
- To determine GD3's impact on NF-kappaB activation and cell death pathways in HepG2 cells under therapeutic stress.
Main Methods:
- HepG2 cells were treated with ionizing radiation or daunorubicin, with or without GD3 pretreatment.
- NF-kappaB activation, Akt phosphorylation, and kappaB-dependent gene expression were assessed.
- Apoptotic cell death, mitochondrial cytochrome c and Smac/Diablo release, and caspase 3 activation were analyzed.
- The effect of cyclosporin A on GD3 and radiation combination therapy was evaluated.
Main Results:
- Ionizing radiation and daunorubicin activated NF-kappaB and upregulated kappaB-dependent genes, with minimal cell death.
- GD3 pretreatment inhibited NF-kappaB nuclear translocation but did not affect Akt phosphorylation.
- GD3 enhanced apoptosis induced by radio- and chemotherapy.
- The combination of GD3 and ionizing radiation triggered reactive oxygen species, mitochondrial release of cytochrome c and Smac/Diablo, and caspase 3 activation.
- Cyclosporin A pretreatment protected cells from the GD3 plus ionizing radiation combination.
Conclusions:
- GD3 sensitizes hepatoblastoma cells to radio- and chemotherapy by inhibiting NF-kappaB activation.
- GD3 promotes apoptosis through mitochondrial pathways, involving cytochrome c and Smac/Diablo release.
- GD3 has potential as an adjuvant therapy to overcome cancer treatment resistance by targeting mitochondria and NF-kappaB.
